# A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

> **NCT00500006** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

## Interventions

- **DRUG:** MK0457
- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00500006
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2015-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500006, "A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00500006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*